Publications

Tomar T, de Jong S, Alkema NG, Meersma GJ, Klip HG, van der Zee AGJ, Wisman GBA; Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Genome Med. 2016 Oct 20;8(1):107.
PMID: 27765068
DOI: 10.1186/s13073-016-0361-5

Read more

Alkema NG*, Tomar T*, Duiker EW, Meersma GJ, Klip HG, van der Zee AGJ, Wisman GBA,de Jong S; Biobanking of patient and patient-derived xenograft (PDX) ovarian tumour tissue: efficient preservation with low and high FCS based methods, Sci Rep. 2015
Oct 6;5:14495.
PMID: 26440065
DOI: 10.1038/srep14495
*Equal contribution

Read more

Joseph JV, van Roosmalen IA, Busschers E, Tomar T, Conroy S, Eggens-Meijer E, Pe├▒aranda Fajardo N, Pore MM, Balasubramanyian V, Wagemakers M, Copray S, den Dunnen WF, Kruyt FA.Serum-Induced Differentiation of Glioblastoma Neurospheres Leads to Enhanced Migration/Invasion Capacity That Is Associated with Increased MMP9.PLoS One. 2015 Dec
23;10(12):e0145393
PMID: 26700636
DOI: 10.1371/journal.pone.0145393

Read more

Joseph JV, Tomar T*, Conroy S*, Eggens-Meijer E, Bhat K, Copray S, Walenkamp AM, Boddeke E,Balasubramanyian V, Wagemakers M, den Dunnen WF, Kruyt FA. TGF-╬▓ is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion.Cell death Dis
2014 Oct 2;5:e1443
PMID: 25275602
DOI: 10.1038/cddis.2014.395
*Equal contribution

Read more

Alkema NG*, Tomar T*, van der Zee AGJ, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA*, Wisman GBA*; Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer; GynecolOncol. 2014 Jun;133(3):591-8
MID: 24657486
DOI: 10.1016/j.ygyno.2014.03.557
*Equal contribution

Read more

Bansal R, Tomar T, Ostman A, Poelstra K, Prakash J; Selective targeting of interferon gamma to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth, Mol Cancer Ther. 2012
Nov;11(11):2419-28
PMID: 22933708
DOI:10.1158/1535-7163.
MCT-11-0758

Read more